EP
VIR icon

Edgestream Partners’s Vir Biotechnology VIR Stock Holding History

Edgestream Partners’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.37M Buy
+134,321
New +$1.28M 0.04% 607
2023
Q4 		– Sell
-106,808
Closed -$1M – 1082
2023
Q3 		$1M Buy
+106,808
New +$1.52M 0.08% 399

Other funds holding VIR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Edgestream Partners's VIR Position: Q2 2026 in Review

Edgestream Partners opened a new position in Vir Biotechnology (VIR) in Q2 2026: 134,321 shares worth $1.37M. The stake represents 0.04% of the portfolio and ranks #607 among its holdings. This is a return to the name: Edgestream Partners previously reported a position in VIR as recently as Q3 2023.

Edgestream Partners first reported a position in VIR in Q3 2023 and has held it in 2 quarters since. 238 funds tracked by Wall St. Rank hold VIR as of Q2 2026.

  • Edgestream Partners held 134,321 shares of Vir Biotechnology worth $1.37M as of Q2 2026.
  • Vir Biotechnology was a new Edgestream Partners position in Q2 2026.
  • Vir Biotechnology made up 0.04% of Edgestream Partners's portfolio in Q2 2026, its #607 holding.
  • Edgestream Partners first reported a position in Vir Biotechnology in Q3 2023 and has held it in 2 quarters since.
  • 238 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2026.

Based on Edgestream Partners's 13F filing for Q2 2026, filed 11 Aug 2026.